Stay updated with breaking news from Ioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New York, New York--(Newsfile Corp. - November 21, 2022) - PCG Digital -- Lexaria Bioscience (NASDAQ: LEXX) is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against
Mito Plus was launched during the Bengaluru Tech Summit, which is being held between 16th and 18th November 2022.
Item 2.02Results of Operations and Financial Condition. On November 18, 2022, Twist Bioscience Corporation issued a press release announcing its financial results for the fourth quarter and... | November 18, 2022
Establishes first-in-class biopharmaceutical commercialization platform specifically addressing rare diseases in Europe Secured exclusive rights in 26 European Countries to an investigational
KELOWNA, BC / ACCESSWIRE / November 10, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program